PISCATAWAY, N.J. — Camber Pharmaceuticals has introduced fesoterodine fumarate extended-release tablets.
According to the Cleveland Clinic, approximately 33 million Americans struggle with overactive bladders, impacting about 30% of adult males and 40% of adult females nationwide.
Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
Fesoterodine fumarate extended-release tablets are available in 30 count bottles in 4 mg and 8 mg strengths.
For more info, please visit https://www.camberpharma.com/products/fesoterodine-fumarate-er/
